Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients
A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone.
The treatment of active Takayasu arteritis (TAK) is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. Our upfront management of TAK, beyond glucocorticoids and conventional DMARDs, remains limited to two primary mechanistic
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.
A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from the U.S. market.
Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.


